

	Pharma & Pharma Tools / Technologies	MedTech / Diagnostics	Digital Health
Pre-Seed / Emerging Technologies			
General Description	Early stage ground-breaking new technologies with disruptive potential. Commercialisation journey initiated (i.e. not just exciting research results, but early business approach identified). Max 1-2 presentations per parallel track.		
Ownership structure	Privately held; company not necessarily formed	Privately held; company not necessarily formed	Privately held; company not necessarily formed
Timeline	Approximately 3 years from initiating clinical trial	Approximately 2-3 years from clinical validation	Approximately 12-18 months from clinical validation
Development stage (Readiness levels)	TRL \approx 4 IPRL \leq 5 CRL \leq 4 FRL \leq 4	TRL \approx 4 IPRL \leq 5 CRL \leq 4 FRL \leq 4	TRL \approx 4 IPRL \leq 5 CRL \leq 4 FRL \leq 4
Team & Board	Founders still heavily involved in company / project.	Founders still heavily involved in company / project.	Founders still heavily involved in company / project.
Growth companies			
General Description	Growth companies developing products / services with international potential. Companies that have already brought in external capital (family offices, government agencies etc) and are now looking for first larger investments (e.g. from VCs). Ca. 10-15 companies per track		
Ownership structure	Privately held company (i.e. not listed on stock exchange)	Privately held company (i.e. not listed on stock exchange)	Privately held company (i.e. not listed on stock exchange)
Timeline	Less than 2 years from initiating clinical trials	Less than 2 years from clinical validation	Less than 18 months from clinical validation
Development stage (Readiness levels)	Late-stage pre-clinical tox (GLP) through to phase 1 clinical trials TRL = 5-6 IPRL \geq 6 CRL \approx 5 FRL = 6-7	System components validated in relevant environment. Preparation for clinical testing (where required, e.g. MedTech class III) TRL = 5-6 IPRL \geq 6 CRL \geq 5 FRL = 6-7	System / process validated in relevant environment, first customer testing TRL = 5-6 IPRL \geq 6 CRL \geq 5 FRL = 6-7
Team & Board	Full-time CEO; other key team members full-time, part-time or on consultant basis. Board	Full-time CEO; other key team members full-time, part-time or on consultant basis. Board	Full-time CEO; other key team members full-time, part-time or on consultant basis. Board

	with experience in pharma product development	with experience in MedTech/diagnostics product development and launches	with experience in digital health product development and market introduction
Series A / B companies			
General Description	Showcase for well-established companies aiming for international expansion. Max 1 per parallel track		
Ownership structure	Privately held company (i.e. not listed on stock exchange)	Privately held company (i.e. not listed on stock exchange)	Privately held company (i.e. not listed on stock exchange)
Timeline	Clinical trials initiated	Clinical validation ongoing or complete	Clinical validation ongoing or complete
Development stage (Readiness levels)	TRL ≥ 6 IPRL ≥ 6 CRL ≥ 6 FRL ≥ 8	TRL ≥ 6 IPRL ≥ 6 CRL ≥ 6 FRL ≥ 8	TRL ≥ 6 IPRL ≥ 6 CRL ≥ 6 FRL ≥ 8
Team	Strong team employed in the company covering all key functions. Professional board with relevant experience for phase of company	Strong team employed in the company covering all key functions. Professional board with relevant experience for phase of company	Strong team employed in the company covering all key functions. Professional board with relevant experience for phase of company